BWXT and Bayer to focus on therapeutic radionuclides
September 16, 2021 -- BWXT Medical and Bayer have entered an agreement to ramp up their supply of actinium-225 as both companies seek to broaden commercialization strategies for targeted radionuclide therapies. Read More
IBA, SCK CEN sign actinium-225 deal
September 15, 2021 -- Proton therapy developer Ion Beam Applications (IBA) and Belgian nuclear research center SCK CEN have partnered to enable the production of the medical radioisotope actinium-225. Read More
Accuray promotes prostate cancer research at ESTRO 2021
September 14, 2021 -- Radiation oncology firm Accuray is highlighting research presented at the recent European Society for Radiotherapy and Oncology (ESTRO) annual congress on the benefits of its CyberKnife robotic radiotherapy platform in prostate cancer treatment. Read More
Lantheus, RefleXion to collaborate on prostate cancer treatment
September 13, 2021 -- Lantheus Medical Imaging parent Lantheus Holdings and radiation therapy equipment developer RefleXion Medical have signed a development and marketing partnership to evaluate the use of Lantheus' prostate-specific membrane antigen-targeted PET agent piflufolastat F-18 with RefleXion's X1 biology-guided radiotherapy system. Read More
B dot Medical unveils scanning magnet for proton therapy
September 10, 2021 -- B dot Medical has manufactured a scanning magnet for a compact proton therapy system currently under development. Read More
ASTRO calls proposed CMS cuts 'draconian'
September 9, 2021 -- The American Society for Radiation Oncology (ASTRO) told the U.S. Centers for Medicare and Medicaid Services (CMS) that its proposed changes to the 2022 Medicare Physician Fee Schedule could lead to draconian cuts in cancer care. Read More
NorthStar, Point Biopharma ink Ac-225 supply deal
September 8, 2021 -- NorthStar Medical Radioisotopes and Point Biopharma Global have signed a supply agreement covering the development and commercialization of the medical radioisotope actinium-225 (Ac-225). Read More
Telix, Kettering to research PSMA radiotracer
September 8, 2021 -- Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix's investigational prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical, illuccix. Read More
Hermes, Isotopia sign deal on dosimetry
September 7, 2021 -- Nuclear medicine software developer Hermes Medical Solutions has signed a collaboration with Isotopia Molecular Imaging to support clinical studies to demonstrate the positive effects of personalized dosimetry and modulated radiopharmaceutical therapy on patient outcomes. Read More
Second-look PET/CT catches cancer spread
September 2, 2021 -- Is a second PET/CT scan worth it before radiotherapy treatment? Swiss clinicians think so, especially when there are delays of more than four weeks after initial scans in patients with advanced head and neck squamous cell cancer, according to a study published August 29 in Clinical and Translational Radiation Oncology. Read More
Special Feature
IMV: Imaging boosts precision in radiation therapy
Radiation therapy is a relatively stable market, with procedure volume growing at an average annual rate of 2%. But major technological changes in radiation oncology are brewing under the surface, according to a new report by IMV Medical Information Division. Read more
VENDOR CONNECT